- Startseite
- All IPOs
- IPO Information OCTOPLUS
OCTOPLUS
Identification
Listing sponsor / Agent
FORTIS
Symbol
OCTO
ISIN code
NL0000345718
Trading location
Amsterdam
ICB
Biotechnology
Activity description
The issuer was founded in 1995 and is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on proprietary drug delivery technologies of the company and have fewer side effects, increased patient convenience and better efficacy than existing therapies.
Website address
http://www.octoplus.nl/index.cfm/octoplus
Operation
IPO date
Mo. 03/12/2007
IPO type
Introduction by public issue of new shares
IPO type
Initial Public offering
Catégorie
IPO
Operation description
Offering of up to 4,9 million newly issued ordinary shares, at a price range of EUR 4,65 to EUR 5,50 per Share.
Operation calendar
Date of first listing: 4 October 2006 Settlement: 9 october 2006
Company profile
OctoPlus is a drug delivery company specialized in the development of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. In addition, the group is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.
Net sales break down by source of income as follows: sales of services (99.6%) and licensing revenues (0.4%).
Net sales are distributed geographically as follows: Europe (34.9%), North America (24.3%) and other (40.8%).
Source:
Cofisem
-
Last Update:
05 Mar 2013
Key Executives
Chief Executive Officer | Jan Hendrik Egberts | ||||
Chief Financial Officer | Susan Swarte | ||||
Communications | Rianne Roukema | ||||
Investor Relations | Rianne Roukema | ||||
Source: Cofisem - Last Update: 04 Jul 2012 |
Key figures
Millenium | 2011 | 2010 | 2009 | 2008 | 2007 |
---|---|---|---|---|---|
Net sales | 7.702 | 8.329 | 19.046 | 16.923 | 5.194 |
Income from ordinary activities | 7.702 | 8.329 | 19.046 | 16.923 | 5.194 |
Operating income | -5.436 | -5.221 | -1.800 | -4.202 | -15.134 |
Cost of net financial indebtedness | -880 | -981 | -1.160 | -1.640 | -33 |
Equity-Accounted companies' contribution to results | |||||
Net profit from discontinued activities | |||||
Net income | -6.316 | -6.202 | -2.957 | -6.209 | -15.175 |
Net income (group share) | -6.316 | -6.202 | -2.957 | -6.209 | -15.175 |
Fiscal year end | 12,11 | 12,10 | 12,09 | 12,08 | 12,07 |
Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
Account Standards | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. | Exercices aux normes IAS-IFRS à compter de l'exercice 2004. |
Source: Cofisem - Last Update: 05 Mar 2013 |